Researchers from the Centro Nacional de Investigaciones Oncológicas aimed to identify pathways that contribute to the metabolic reprogramming ability of cancer cells upon resistance to ataxia-telangiectasia-mutated (ATM) inhibition. Metabolism-centered CRISPR screening identified Kelch-like ECH-associated protein 1 (KEAP1), which is an oxidative stress sensor that controls the Nrf2-regulated antioxidant pathway, as a key factor involved in desensitizing cancer cells to ATM inhibition.
Lift Biosciences Ltd. and Minaris Regenerative Medicine GmbH have entered into a development and manufacturing partnership for N-Lift, Lift's first-in-class neutrophil progenitor-based leukocyte infusion therapy for the treatment of various cancer indications, including pancreatic cancer, lung cancer and other solid tumors.
Lateral Pharma Pty. Ltd. has discovered peptides targeting LanC-like (LANCL) proteins reported to be useful for the treatment of diabetes, infections, inflammation, obesity, pain, metabolic, muscle and neurological disorders, among others.
Hookipa Pharma Inc. has achieved a US$10 million milestone payment under its collaboration agreement with Roche (F. Hoffmann-La Roche Ltd.) to develop HB-700, a novel arenaviral immunotherapy for KRAS-mutated cancers.
Legochem Biosciences Inc. has entered into a license agreement with Elthera AG to develop and commercialize a novel antibody-drug conjugate (ADC) therapy using a monoclonal antibody developed by Elthera.
Acea Therapeutics Inc. and Hangzhou Acea Biosciences Co. Ltd. have described heterocyclic compounds acting as tyrosine kinase inhibitors reported to be useful for the treatment of cancer.
Humanwell Healthcare (Group) Co. Ltd. has identified transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer.
Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have divulged trideuteromethyl-substituted pyrazino pyrazino quinolinone derivatives acting as deuterated GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.
Lung and pancreatic cancer cells usually become chemotherapy resistant; the alternative to target nonapoptotic pathways was hypothesized as an approach for treating these cancers. Researchers from Sun Yat-sen University and their collaborators focused on the activation of pyroptosis as a therapeutic alternative to treat these resistant tumor types.
Dxcover Ltd. raised $9.25 million (£7.5 million) in a series A fundraising round and received a grant of $2.7 million (£2.2 million) from the European Innovation Council to support development of the company’s liquid biopsy platform for the detection of multiple early-stage cancers. Existing investors Eos Advisory LLP, Mercia Asset Management plc, Scottish Enterprise, University of Strathclyde, SIS Ventures and Norcliffe Capital led the round, which was also joined by Mark Banforth of Thairm Bio.
